Accueil>>Signaling Pathways>> GPCR/G protein>> Sigma Receptor>>σ1 Receptor antagonist-1

σ1 Receptor antagonist-1

Catalog No.GC62708

σ1 L'antagoniste des récepteurs-1 est un antagoniste des récepteurs sigma 1 très puissant et sélectif (pKi = 10,28).

Products are for research use only. Not for human use. We do not sell to patients.

σ1 Receptor antagonist-1 Chemical Structure

Cas No.: 1204401-49-9

Taille Prix Stock Qté
5 mg
86,00 $US
En stock
10 mg
135,00 $US
En stock
25 mg
288,00 $US
En stock
50 mg
468,00 $US
En stock
100 mg
765,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

σ1 Receptor antagonist-1 is a highly potent and selective sigma 1 receptor antagonist (pKi=10.28). σ1 Receptor antagonist-1 inhibits cell growth, arrests cell cycle at G0/G1 phase and induces apoptosis of MCF-7/ADR cells[1].

σ1 Receptor antagonist-1 (compound 9) (10 μM; 48 hours) inhibits cell growth, arrests cell cycle at G0/G1 phase and induces apoptosis of MCF-7/ADR cells[1].

Pretreatment withσ1 Receptor antagonist-1 (1 mg/kg; s.c.) significantly increases the anti-nociceptive effect produces by morphine over the entire time course starting at 60 min[1].

[1]. Piergentili A, et al. Novel highly potent and selective sigma 1 receptor antagonists related to spipethiane. J Med Chem. 2010;53(3):1261-1269.

Avis

Review for σ1 Receptor antagonist-1

Average Rating: 5 ★★★★★ (Based on Reviews and 9 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for σ1 Receptor antagonist-1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.